Van ECK Associates Corp reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 3.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 157,013 shares of the life sciences company’s stock after selling 4,950 shares during the quarter. Van ECK Associates Corp owned about 0.11% of Illumina worth $31,277,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in ILMN. Advisory Services Network LLC raised its holdings in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the period. Penserra Capital Management LLC raised its holdings in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after acquiring an additional 102 shares during the period. Dupont Capital Management Corp bought a new position in Illumina in the 3rd quarter valued at about $153,000. Paradigm Asset Management Co. LLC raised its holdings in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares during the period. Finally, NN Investment Partners Holdings N.V. raised its holdings in Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after acquiring an additional 100 shares during the period. 90.76% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $214.86 on Friday. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The stock has a market cap of $31,441.10, a P/E ratio of 62.97, a P/E/G ratio of 3.56 and a beta of 0.74. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $216.08.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the business posted $0.97 EPS. analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

Several research analysts have weighed in on the stock. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Citigroup Inc. increased their price target on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Barclays PLC increased their price target on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Bank of America Corporation increased their price target on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reissued a “market perform” rating and issued a $205.00 price target (up from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $200.88.

In related news, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total transaction of $29,827.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the sale, the senior vice president now owns 24,908 shares in the company, valued at approximately $5,263,807.64. The disclosure for this sale can be found here. Insiders have sold a total of 192,446 shares of company stock worth $39,713,114 in the last quarter. 0.89% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/illumina-inc-ilmn-shares-sold-by-van-eck-associates-corp/1725217.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.